Maryland biotechnology firms Profectus BioSciences Inc. and Emergent BioSolutions Inc. will receive up to $36 million to develop and manufacture a new vaccine against a type of virus that causes hemorrhagic fever. The project will be funded by Coalition for Epidemic Preparedness Innovations (CEPI), based in Norway, which aims to develop vaccines to stop future epidemics. The vaccine Profectus and Emergent will work on targets the Lassa virus, which infects an estimated 100,000 to 300,000 annually.…
from https://www.bizjournals.com/baltimore/news/2018/08/16/two-marylandbiotechs-get-36-million-to-aid-in-new.html?ana=RSS&s=article_search
via http://baltimorecheckbook.tumblr.com/post/177061744157
No comments:
Post a Comment